In this video from The Motley Fool's "Ask a Fool" series, Fool health-care analyst Max Macaluso takes a question from a Fool reader, who asks, "What is your Foolish opinion of Horizon Pharma (NASDAQ:HZNP)?" This commercial-stage biotech company has seen its shares blow through the roof over the past year, up a staggering 475% over the past 12 months. What has driven this white-hot run, and is there still time for investors to get in? Max breaks the company's success down to three key factors that investors need to be aware of, and isolates one major risk shareholders could face from here.

Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.